TNGX
insider transactionsTango Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-131.5K
0 buy · 131.5K sell
Net value · 90d
-$3.0M
$0 in · $3.0M out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
7
0 buy · 131.5K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
25.0K sh
Own New
-
Grant·A
Director
$0
4.0K sh
Own +11%
-
Grant·A
Director
$0
3.6K sh
Own New
-
Grant·A
Director
$0
570 sh
Own +3%
-
Grant·A
Director
$0
25.0K sh
Own New
-
Grant·A
Director
$0
4.0K sh
Own +19%
-
Grant·A
Director
$0
25.0K sh
Own New
-
Grant·A
Director
$0
4.0K sh
Own +32%
-
Exercise·M
Crystal Adam KEY
President, R&D · 10b5-1
$0
27.0K sh
Own +9%
-
Sell·S
Crystal Adam KEY
President, R&D · 10b5-1
$480.9K
20.9K sh · $23.06
Own -15%
-
Sell·S
Crystal Adam KEY
President, R&D · 10b5-1
$136.6K
6.1K sh · $22.25
Own -4%
-
Exercise·M
Crystal Adam KEY
President, R&D · 10b5-1
$140.4K
27.0K sh · $5.20
Own +23%
-
Grant·A
Gall Matthew KEY
Chief Financial Officer
$0
240.0K sh
Own New
-
Grant·A
Gall Matthew KEY
Chief Financial Officer
$0
40.0K sh
Own New
-
Exercise·M
Crystal Adam KEY
President, R&D · 10b5-1
$0
27.0K sh
Own +8%
-
Sell·S
Crystal Adam KEY
President, R&D · 10b5-1
$24.2K
1.1K sh · $22.00
Own -1%
-
Sell·S
Crystal Adam KEY
President, R&D · 10b5-1
$548.9K
25.9K sh · $21.19
Own -18%
-
Exercise·M
Crystal Adam KEY
President, R&D · 10b5-1
$140.4K
27.0K sh · $5.20
Own +23%
-
Grant·A
Director
$0
5.2K sh
Own New
-
Grant·A
Director
$0
12.3K sh
Own +123%
-
Exercise·M
Crystal Adam KEY
President, R&D · 10b5-1
$0
38.5K sh
Own +11%
-
Sell·S
Crystal Adam KEY
President, R&D · 10b5-1
$961.5K
38.5K sh · $25.00
Own -25%
-
Exercise·M
Crystal Adam KEY
President, R&D · 10b5-1
$200.0K
38.5K sh · $5.20
Own +34%
-
Exercise·M
Crystal Adam KEY
President, R&D · 10b5-1
$0
27.0K sh
Own +7%
-
Sell·S
Crystal Adam KEY
President, R&D · 10b5-1
$572.5K
27.0K sh · $21.20
Own -19%
-
Exercise·M
Crystal Adam KEY
President, R&D · 10b5-1
$140.4K
27.0K sh · $5.20
Own +24%
-
Exercise·M
Crystal Adam KEY
President, R&D · 10b5-1
$0
12.0K sh
Own +3%
-
Sell·S
Crystal Adam KEY
President, R&D · 10b5-1
$241.3K
12.0K sh · $20.11
Own -10%
-
Exercise·M
Crystal Adam KEY
President, R&D · 10b5-1
$62.4K
12.0K sh · $5.20
Own +11%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 5, 2026 | Rothenberg Mace | Grant A | 25.0K | $0 |
| Jun 5, 2026 | Rothenberg Mace | Grant A | 4.0K | $0 |
| Jun 5, 2026 | Lee Sung | Grant A | 3.6K | $0 |
| Jun 5, 2026 | Lee Sung | Grant A | 570 | $0 |
| Jun 5, 2026 | Ketchum John B | Grant A | 25.0K | $0 |
| Jun 5, 2026 | Ketchum John B | Grant A | 4.0K | $0 |
| Jun 5, 2026 | Calhoun Lesley Ann | Grant A | 25.0K | $0 |
| Jun 5, 2026 | Calhoun Lesley Ann | Grant A | 4.0K | $0 |
| Jun 1, 2026 | Crystal Adam KEY 10b5-1 | Exercise M | 27.0K | $0 |
| Jun 1, 2026 | Crystal Adam KEY 10b5-1 | Sell S | 20.9K | $480.9K |
| Jun 1, 2026 | Crystal Adam KEY 10b5-1 | Sell S | 6.1K | $136.6K |
| Jun 1, 2026 | Crystal Adam KEY 10b5-1 | Exercise M | 27.0K | $140.4K |
| May 1, 2026 | Gall Matthew KEY | Grant A | 240.0K | $0 |
| May 1, 2026 | Gall Matthew KEY | Grant A | 40.0K | $0 |
| May 1, 2026 | Crystal Adam KEY 10b5-1 | Exercise M | 27.0K | $0 |
| May 1, 2026 | Crystal Adam KEY 10b5-1 | Sell S | 1.1K | $24.2K |
| May 1, 2026 | Crystal Adam KEY 10b5-1 | Sell S | 25.9K | $548.9K |
| May 1, 2026 | Crystal Adam KEY 10b5-1 | Exercise M | 27.0K | $140.4K |
| Apr 29, 2026 | Lee Sung | Grant A | 5.2K | $0 |
| Apr 29, 2026 | Lee Sung | Grant A | 12.3K | $0 |
| Apr 15, 2026 | Crystal Adam KEY 10b5-1 | Exercise M | 38.5K | $0 |
| Apr 15, 2026 | Crystal Adam KEY 10b5-1 | Sell S | 38.5K | $961.5K |
| Apr 15, 2026 | Crystal Adam KEY 10b5-1 | Exercise M | 38.5K | $200.0K |
| Apr 1, 2026 | Crystal Adam KEY 10b5-1 | Exercise M | 27.0K | $0 |
| Apr 1, 2026 | Crystal Adam KEY 10b5-1 | Sell S | 27.0K | $572.5K |
| Apr 1, 2026 | Crystal Adam KEY 10b5-1 | Exercise M | 27.0K | $140.4K |
| Mar 25, 2026 | Crystal Adam KEY 10b5-1 | Exercise M | 12.0K | $0 |
| Mar 25, 2026 | Crystal Adam KEY 10b5-1 | Sell S | 12.0K | $241.3K |
| Mar 25, 2026 | Crystal Adam KEY 10b5-1 | Exercise M | 12.0K | $62.4K |
About TNGX insider trading
This page tracks insider transactions for Tango Therapeutics, Inc. (TNGX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.